A Study to See Whether Memantine Helps Reduce the Urge to Drink Alcohol in People with Alcohol Addiction Using a Brain Scan

INTERVENTION: Intervention1: drug intervention: In this trial memantine is used as an adjunct to naltrexone after detoxification and baseline assessments Patients in the intervention group receive naltrexone 50 mg once daily plus memantine titrated gradually 5 mg per day in week 1 10 mg per day in week 2 and 20 mg per day from week 3 onward continued once daily for a total of si Xweeks MRS will be done at baseline and after 6 weeks and 1H MRS metabolite will be compared between this group and control group clinical craving will be measured by scales OCDUS ACQ at baseline and after 6 weeks and will be compared with control group Control Intervention1: control group: the control group receives only naltrexone 50mg once daily for 6 weeks allowing comparison of clinical craving measures and anterior cingulate corte X1H MRS metabolite changes between adjunctive memantine and naltrexone alone CONDITION: Health Condition 1: F102‐ Alcohol dependence PRIMARY OUTCOME: Change in craving assessed by Alcohol craving questionnaire and Obsessive compulsive drinking scale from baseline to day 42 ; Timepoint: on the day of intervention and after 42 days SECONDARY OUTCOME: Change in gamma aminobutyric acid GABA N acetyl aspartyl NAA glutamate Glu glutamine Gln glutaminergic compounds Gl Xmyoinositol MI levels in ACC at baseline and at 42 daysTimepoint: on the day of intervention and after 42 days INCLUSION CRITERIA: Patients diagnosed with alcohol dependence current use continuous as per international classification of diseases 11th Male gender Patients with mild to moderate depression Age between 18 and 50 yrs Ready to give informed consent Patients with Ciwa Ar score less than 10